nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1A1—Clobetasol propionate—psoriasis	0.142	0.187	CbGbCtD
Flutamide—CYP1A1—Methoxsalen—psoriasis	0.0745	0.0981	CbGbCtD
Flutamide—CYP3A5—Beclomethasone—psoriasis	0.0646	0.085	CbGbCtD
Flutamide—CYP1A2—Clobetasol propionate—psoriasis	0.0634	0.0834	CbGbCtD
Flutamide—CYP1A1—Cholecalciferol—psoriasis	0.0494	0.065	CbGbCtD
Flutamide—CYP1B1—Dexamethasone—psoriasis	0.0487	0.0641	CbGbCtD
Flutamide—CYP1A2—Methoxsalen—psoriasis	0.0333	0.0438	CbGbCtD
Flutamide—CYP3A5—Mycophenolate mofetil—psoriasis	0.0257	0.0338	CbGbCtD
Flutamide—CYP2C19—Cholecalciferol—psoriasis	0.0239	0.0315	CbGbCtD
Flutamide—CYP3A4—Calcitriol—psoriasis	0.0224	0.0295	CbGbCtD
Flutamide—CYP1A1—Dexamethasone—psoriasis	0.0214	0.0281	CbGbCtD
Flutamide—CYP3A5—Hydrocortisone—psoriasis	0.0206	0.0271	CbGbCtD
Flutamide—CYP3A5—Cyclosporine—psoriasis	0.0195	0.0256	CbGbCtD
Flutamide—CYP3A4—Methoxsalen—psoriasis	0.0174	0.023	CbGbCtD
Flutamide—CYP2C19—Prednisone—psoriasis	0.0166	0.0218	CbGbCtD
Flutamide—CYP2C19—Cyclosporine—psoriasis	0.0157	0.0207	CbGbCtD
Flutamide—CYP3A5—Dexamethasone—psoriasis	0.0128	0.0169	CbGbCtD
Flutamide—CYP3A4—Cholecalciferol—psoriasis	0.0116	0.0152	CbGbCtD
Flutamide—CYP2C19—Dexamethasone—psoriasis	0.0103	0.0136	CbGbCtD
Flutamide—CYP3A4—Triamcinolone—psoriasis	0.01	0.0132	CbGbCtD
Flutamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.01	0.0132	CbGbCtD
Flutamide—CYP3A4—Betamethasone—psoriasis	0.0086	0.0113	CbGbCtD
Flutamide—CYP3A4—Prednisolone—psoriasis	0.00848	0.0112	CbGbCtD
Flutamide—CYP3A4—Hydrocortisone—psoriasis	0.00804	0.0106	CbGbCtD
Flutamide—CYP3A4—Prednisone—psoriasis	0.00801	0.0105	CbGbCtD
Flutamide—CYP3A4—Cyclosporine—psoriasis	0.00759	0.01	CbGbCtD
Flutamide—CYP3A4—Dexamethasone—psoriasis	0.005	0.00658	CbGbCtD
Flutamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00199	0.0369	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00174	0.0322	CbGpPWpGaD
Flutamide—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00159	0.0296	CbGpPWpGaD
Flutamide—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.0015	0.0279	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00131	0.0243	CbGpPWpGaD
Flutamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00123	0.0229	CbGpPWpGaD
Flutamide—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00101	0.0188	CbGpPWpGaD
Flutamide—CYP1B1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.001	0.0186	CbGpPWpGaD
Flutamide—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000959	0.0178	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000915	0.017	CbGpPWpGaD
Flutamide—CYP1B1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000822	0.0153	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000746	0.0139	CbGpPWpGaD
Flutamide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00074	0.0138	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.000677	0.0126	CbGpPWpGaD
Flutamide—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.00067	0.0125	CbGpPWpGaD
Flutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000661	0.0123	CbGpPWpGaD
Flutamide—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.00066	0.0123	CbGpPWpGaD
Flutamide—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000652	0.0121	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000645	0.012	CbGpPWpGaD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000625	0.0116	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000621	0.0115	CbGpPWpGaD
Flutamide—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000616	0.0115	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—SOCS1—psoriasis	0.000616	0.0114	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.00059	0.011	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000563	0.0105	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000553	0.0103	CbGpPWpGaD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000536	0.00996	CbGpPWpGaD
Flutamide—AR—Nuclear Receptors—VDR—psoriasis	0.000514	0.00956	CbGpPWpGaD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000511	0.0095	CbGpPWpGaD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000506	0.00941	CbGpPWpGaD
Flutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000504	0.00937	CbGpPWpGaD
Flutamide—CYP1B1—Estrogen Receptor Pathway—JUN—psoriasis	0.000497	0.00924	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000487	0.00904	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000483	0.00897	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000483	0.00897	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—LEP—psoriasis	0.000455	0.00845	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000443	0.00824	CbGpPWpGaD
Flutamide—CYP1B1—Biological oxidations—CYP2S1—psoriasis	0.000437	0.00812	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.000436	0.0081	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—CYP2S1—psoriasis	0.000431	0.008	CbGpPWpGaD
Flutamide—CYP1B1—Estrogen Receptor Pathway—STAT3—psoriasis	0.00043	0.00799	CbGpPWpGaD
Flutamide—CYP1B1—Melatonin metabolism and effects—APOE—psoriasis	0.000423	0.00787	CbGpPWpGaD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000414	0.0077	CbGpPWpGaD
Flutamide—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000406	0.00755	CbGpPWpGaD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000398	0.0074	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—PPARG—psoriasis	0.000396	0.00736	CbGpPWpGaD
Flutamide—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000393	0.0073	CbGpPWpGaD
Flutamide—CYP1B1—Tryptophan metabolism—CAT—psoriasis	0.000377	0.007	CbGpPWpGaD
Flutamide—AR—Nuclear Receptors—PPARG—psoriasis	0.000359	0.00666	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000327	0.00608	CbGpPWpGaD
Flutamide—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000327	0.00607	CbGpPWpGaD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000323	0.006	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—LEP—psoriasis	0.000321	0.00596	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000308	0.00572	CbGpPWpGaD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000307	0.00571	CbGpPWpGaD
Flutamide—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000306	0.00569	CbGpPWpGaD
Flutamide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000303	0.00564	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.0003	0.00557	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—NOS2—psoriasis	0.000299	0.00555	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000285	0.00529	CbGpPWpGaD
Flutamide—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000283	0.00527	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000281	0.00522	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000281	0.00522	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—PPARG—psoriasis	0.000279	0.00519	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000273	0.00507	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000269	0.005	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000265	0.00493	CbGpPWpGaD
Flutamide—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000265	0.00492	CbGpPWpGaD
Flutamide—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000261	0.00485	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—IL13—psoriasis	0.000258	0.0048	CbGpPWpGaD
Flutamide—CYP1B1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000252	0.00468	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000249	0.00463	CbGpPWpGaD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000249	0.00463	CbGpPWpGaD
Flutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000246	0.00457	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—STAT3—psoriasis	0.000243	0.00451	CbGpPWpGaD
Flutamide—Hyperglycaemia—Betamethasone—psoriasis	0.00024	0.00129	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.00024	0.00446	CbGpPWpGaD
Flutamide—AR—Notch-mediated HES/HEY network—CD4—psoriasis	0.00024	0.00445	CbGpPWpGaD
Flutamide—Tension—Cyclosporine—psoriasis	0.00024	0.00129	CcSEcCtD
Flutamide—Skin disorder—Mycophenolic acid—psoriasis	0.000239	0.00128	CcSEcCtD
Flutamide—Vomiting—Acitretin—psoriasis	0.000238	0.00128	CcSEcCtD
Flutamide—Vomiting—Fluocinolone Acetonide—psoriasis	0.000238	0.00127	CcSEcCtD
Flutamide—Nervousness—Cyclosporine—psoriasis	0.000237	0.00127	CcSEcCtD
Flutamide—Rash—Acitretin—psoriasis	0.000236	0.00127	CcSEcCtD
Flutamide—Dermatitis—Acitretin—psoriasis	0.000236	0.00127	CcSEcCtD
Flutamide—Rash—Fluocinolone Acetonide—psoriasis	0.000236	0.00126	CcSEcCtD
Flutamide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000235	0.00126	CcSEcCtD
Flutamide—Anorexia—Mycophenolic acid—psoriasis	0.000235	0.00126	CcSEcCtD
Flutamide—Headache—Acitretin—psoriasis	0.000235	0.00126	CcSEcCtD
Flutamide—Headache—Fluocinolone Acetonide—psoriasis	0.000234	0.00126	CcSEcCtD
Flutamide—Tension—Mycophenolate mofetil—psoriasis	0.000234	0.00125	CcSEcCtD
Flutamide—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000232	0.00431	CbGpPWpGaD
Flutamide—Nervousness—Mycophenolate mofetil—psoriasis	0.000231	0.00124	CcSEcCtD
Flutamide—Ill-defined disorder—Cyclosporine—psoriasis	0.000227	0.00122	CcSEcCtD
Flutamide—AR—FOXA1 transcription factor network—JUN—psoriasis	0.000226	0.0042	CbGpPWpGaD
Flutamide—Anaemia—Cyclosporine—psoriasis	0.000226	0.00121	CcSEcCtD
Flutamide—Insomnia—Mycophenolic acid—psoriasis	0.000223	0.00119	CcSEcCtD
Flutamide—Nausea—Acitretin—psoriasis	0.000223	0.00119	CcSEcCtD
Flutamide—Erythema—Prednisolone—psoriasis	0.000222	0.00119	CcSEcCtD
Flutamide—Nausea—Fluocinolone Acetonide—psoriasis	0.000222	0.00119	CcSEcCtD
Flutamide—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.000221	0.00119	CcSEcCtD
Flutamide—Malaise—Cyclosporine—psoriasis	0.00022	0.00118	CcSEcCtD
Flutamide—Anaemia—Mycophenolate mofetil—psoriasis	0.00022	0.00118	CcSEcCtD
Flutamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.00022	0.00409	CbGpPWpGaD
Flutamide—Somnolence—Mycophenolic acid—psoriasis	0.000219	0.00117	CcSEcCtD
Flutamide—Leukopenia—Cyclosporine—psoriasis	0.000219	0.00117	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000218	0.00404	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000217	0.00403	CbGpPWpGaD
Flutamide—Erythema—Hydrocortisone—psoriasis	0.000217	0.00116	CcSEcCtD
Flutamide—Malaise—Mycophenolate mofetil—psoriasis	0.000215	0.00115	CcSEcCtD
Flutamide—Decreased appetite—Mycophenolic acid—psoriasis	0.000214	0.00115	CcSEcCtD
Flutamide—Erectile dysfunction—Prednisone—psoriasis	0.000213	0.00114	CcSEcCtD
Flutamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000213	0.00397	CbGpPWpGaD
Flutamide—Leukopenia—Mycophenolate mofetil—psoriasis	0.000213	0.00114	CcSEcCtD
Flutamide—Fatigue—Mycophenolic acid—psoriasis	0.000212	0.00114	CcSEcCtD
Flutamide—Asthenia—Hydroxyurea—psoriasis	0.000211	0.00113	CcSEcCtD
Flutamide—Hypertension—Cyclosporine—psoriasis	0.000211	0.00113	CcSEcCtD
Flutamide—Constipation—Mycophenolic acid—psoriasis	0.000211	0.00113	CcSEcCtD
Flutamide—AHR—Adipogenesis—TNF—psoriasis	0.00021	0.00391	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000209	0.00389	CbGpPWpGaD
Flutamide—Hyperglycaemia—Prednisone—psoriasis	0.000209	0.00112	CcSEcCtD
Flutamide—Anxiety—Cyclosporine—psoriasis	0.000207	0.00111	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000207	0.00111	CcSEcCtD
Flutamide—Ill-defined disorder—Prednisolone—psoriasis	0.000206	0.00111	CcSEcCtD
Flutamide—Hypertension—Mycophenolate mofetil—psoriasis	0.000206	0.0011	CcSEcCtD
Flutamide—Discomfort—Cyclosporine—psoriasis	0.000205	0.0011	CcSEcCtD
Flutamide—Erythema—Triamcinolone—psoriasis	0.000204	0.0011	CcSEcCtD
Flutamide—Feeling abnormal—Mycophenolic acid—psoriasis	0.000203	0.00109	CcSEcCtD
Flutamide—Anxiety—Mycophenolate mofetil—psoriasis	0.000202	0.00108	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000202	0.00108	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000201	0.00108	CcSEcCtD
Flutamide—Ill-defined disorder—Hydrocortisone—psoriasis	0.000201	0.00108	CcSEcCtD
Flutamide—Diarrhoea—Hydroxyurea—psoriasis	0.000201	0.00108	CcSEcCtD
Flutamide—Confusional state—Cyclosporine—psoriasis	0.000201	0.00108	CcSEcCtD
Flutamide—Malaise—Prednisolone—psoriasis	0.0002	0.00107	CcSEcCtD
Flutamide—Discomfort—Mycophenolate mofetil—psoriasis	0.0002	0.00107	CcSEcCtD
Flutamide—Oedema—Cyclosporine—psoriasis	0.000199	0.00107	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—JUN—psoriasis	0.000198	0.00368	CbGpPWpGaD
Flutamide—Confusional state—Mycophenolate mofetil—psoriasis	0.000196	0.00105	CcSEcCtD
Flutamide—Malaise—Hydrocortisone—psoriasis	0.000196	0.00105	CcSEcCtD
Flutamide—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000195	0.00363	CbGpPWpGaD
Flutamide—Thrombocytopenia—Cyclosporine—psoriasis	0.000195	0.00105	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—JUN—psoriasis	0.000195	0.00362	CbGpPWpGaD
Flutamide—Dizziness—Hydroxyurea—psoriasis	0.000195	0.00104	CcSEcCtD
Flutamide—Oedema—Mycophenolate mofetil—psoriasis	0.000194	0.00104	CcSEcCtD
Flutamide—Skin disorder—Cyclosporine—psoriasis	0.000194	0.00104	CcSEcCtD
Flutamide—Hypertension—Prednisolone—psoriasis	0.000192	0.00103	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000191	0.00355	CbGpPWpGaD
Flutamide—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.00019	0.00102	CcSEcCtD
Flutamide—Anorexia—Cyclosporine—psoriasis	0.00019	0.00102	CcSEcCtD
Flutamide—Ill-defined disorder—Triamcinolone—psoriasis	0.00019	0.00102	CcSEcCtD
Flutamide—Skin disorder—Mycophenolate mofetil—psoriasis	0.000189	0.00101	CcSEcCtD
Flutamide—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000188	0.00349	CbGpPWpGaD
Flutamide—Hypertension—Hydrocortisone—psoriasis	0.000187	0.001	CcSEcCtD
Flutamide—Vomiting—Hydroxyurea—psoriasis	0.000187	0.001	CcSEcCtD
Flutamide—Discomfort—Prednisolone—psoriasis	0.000187	0.001	CcSEcCtD
Flutamide—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	0.000186	0.00345	CbGpPWpGaD
Flutamide—Rash—Hydroxyurea—psoriasis	0.000185	0.000995	CcSEcCtD
Flutamide—Erythema—Betamethasone—psoriasis	0.000185	0.000994	CcSEcCtD
Flutamide—Erythema—Dexamethasone—psoriasis	0.000185	0.000994	CcSEcCtD
Flutamide—Anorexia—Mycophenolate mofetil—psoriasis	0.000185	0.000994	CcSEcCtD
Flutamide—Dermatitis—Hydroxyurea—psoriasis	0.000185	0.000994	CcSEcCtD
Flutamide—Malaise—Triamcinolone—psoriasis	0.000184	0.000988	CcSEcCtD
Flutamide—Headache—Hydroxyurea—psoriasis	0.000184	0.000988	CcSEcCtD
Flutamide—Anxiety—Hydrocortisone—psoriasis	0.000184	0.000987	CcSEcCtD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000184	0.00342	CbGpPWpGaD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000184	0.000984	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000183	0.0034	CbGpPWpGaD
Flutamide—Discomfort—Hydrocortisone—psoriasis	0.000183	0.000979	CcSEcCtD
Flutamide—Oedema—Prednisolone—psoriasis	0.000181	0.000973	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000181	0.00336	CbGpPWpGaD
Flutamide—Insomnia—Cyclosporine—psoriasis	0.00018	0.000967	CcSEcCtD
Flutamide—AR—Gene Expression—TARS—psoriasis	0.00018	0.00334	CbGpPWpGaD
Flutamide—Erectile dysfunction—Methotrexate—psoriasis	0.000178	0.000957	CcSEcCtD
Flutamide—Somnolence—Cyclosporine—psoriasis	0.000177	0.00095	CcSEcCtD
Flutamide—Oedema—Hydrocortisone—psoriasis	0.000177	0.00095	CcSEcCtD
Flutamide—Photosensitivity reaction—Methotrexate—psoriasis	0.000177	0.000948	CcSEcCtD
Flutamide—Asthenia—Mycophenolic acid—psoriasis	0.000177	0.000948	CcSEcCtD
Flutamide—Hypertension—Triamcinolone—psoriasis	0.000176	0.000946	CcSEcCtD
Flutamide—Insomnia—Mycophenolate mofetil—psoriasis	0.000176	0.000943	CcSEcCtD
Flutamide—Nausea—Hydroxyurea—psoriasis	0.000175	0.000937	CcSEcCtD
Flutamide—Pruritus—Mycophenolic acid—psoriasis	0.000174	0.000935	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000174	0.00324	CbGpPWpGaD
Flutamide—Decreased appetite—Cyclosporine—psoriasis	0.000173	0.000929	CcSEcCtD
Flutamide—Somnolence—Mycophenolate mofetil—psoriasis	0.000173	0.000927	CcSEcCtD
Flutamide—Drowsiness—Methotrexate—psoriasis	0.000173	0.000926	CcSEcCtD
Flutamide—Skin disorder—Hydrocortisone—psoriasis	0.000172	0.000923	CcSEcCtD
Flutamide—Ill-defined disorder—Dexamethasone—psoriasis	0.000172	0.000923	CcSEcCtD
Flutamide—Ill-defined disorder—Betamethasone—psoriasis	0.000172	0.000923	CcSEcCtD
Flutamide—Discomfort—Triamcinolone—psoriasis	0.000172	0.000922	CcSEcCtD
Flutamide—Fatigue—Cyclosporine—psoriasis	0.000172	0.000921	CcSEcCtD
Flutamide—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000171	0.00319	CbGpPWpGaD
Flutamide—Constipation—Cyclosporine—psoriasis	0.00017	0.000914	CcSEcCtD
Flutamide—AHR—Adipogenesis—IL6—psoriasis	0.00017	0.00315	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000169	0.00314	CbGpPWpGaD
Flutamide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000169	0.000906	CcSEcCtD
Flutamide—Anorexia—Hydrocortisone—psoriasis	0.000169	0.000905	CcSEcCtD
Flutamide—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000169	0.00314	CbGpPWpGaD
Flutamide—Diarrhoea—Mycophenolic acid—psoriasis	0.000169	0.000904	CcSEcCtD
Flutamide—Malaise—Betamethasone—psoriasis	0.000167	0.000897	CcSEcCtD
Flutamide—Malaise—Dexamethasone—psoriasis	0.000167	0.000897	CcSEcCtD
Flutamide—Oedema—Triamcinolone—psoriasis	0.000167	0.000894	CcSEcCtD
Flutamide—Constipation—Mycophenolate mofetil—psoriasis	0.000166	0.000892	CcSEcCtD
Flutamide—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000166	0.00309	CbGpPWpGaD
Flutamide—Haematuria—Methotrexate—psoriasis	0.000165	0.000883	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000164	0.00306	CbGpPWpGaD
Flutamide—Feeling abnormal—Cyclosporine—psoriasis	0.000164	0.000881	CcSEcCtD
Flutamide—Insomnia—Prednisolone—psoriasis	0.000164	0.00088	CcSEcCtD
Flutamide—Dizziness—Mycophenolic acid—psoriasis	0.000163	0.000874	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—IL10—psoriasis	0.000162	0.003	CbGpPWpGaD
Flutamide—Erythema—Prednisone—psoriasis	0.000162	0.000866	CcSEcCtD
Flutamide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.00016	0.000859	CcSEcCtD
Flutamide—Insomnia—Hydrocortisone—psoriasis	0.00016	0.000859	CcSEcCtD
Flutamide—Hypertension—Dexamethasone—psoriasis	0.00016	0.000859	CcSEcCtD
Flutamide—Hypertension—Betamethasone—psoriasis	0.00016	0.000859	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000158	0.00294	CbGpPWpGaD
Flutamide—Anxiety—Dexamethasone—psoriasis	0.000157	0.000844	CcSEcCtD
Flutamide—Anxiety—Betamethasone—psoriasis	0.000157	0.000844	CcSEcCtD
Flutamide—Vomiting—Mycophenolic acid—psoriasis	0.000157	0.00084	CcSEcCtD
Flutamide—Discomfort—Dexamethasone—psoriasis	0.000156	0.000836	CcSEcCtD
Flutamide—Discomfort—Betamethasone—psoriasis	0.000156	0.000836	CcSEcCtD
Flutamide—Rash—Mycophenolic acid—psoriasis	0.000155	0.000833	CcSEcCtD
Flutamide—Dermatitis—Mycophenolic acid—psoriasis	0.000155	0.000832	CcSEcCtD
Flutamide—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000155	0.00288	CbGpPWpGaD
Flutamide—Hepatitis—Methotrexate—psoriasis	0.000155	0.000831	CcSEcCtD
Flutamide—Headache—Mycophenolic acid—psoriasis	0.000154	0.000828	CcSEcCtD
Flutamide—Decreased appetite—Hydrocortisone—psoriasis	0.000154	0.000826	CcSEcCtD
Flutamide—Fatigue—Hydrocortisone—psoriasis	0.000153	0.000819	CcSEcCtD
Flutamide—Oedema—Dexamethasone—psoriasis	0.000151	0.000812	CcSEcCtD
Flutamide—Oedema—Betamethasone—psoriasis	0.000151	0.000812	CcSEcCtD
Flutamide—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000151	0.0028	CbGpPWpGaD
Flutamide—Insomnia—Triamcinolone—psoriasis	0.000151	0.000809	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000151	0.0028	CbGpPWpGaD
Flutamide—Ill-defined disorder—Prednisone—psoriasis	0.00015	0.000803	CcSEcCtD
Flutamide—Feeling abnormal—Prednisolone—psoriasis	0.000149	0.000801	CcSEcCtD
Flutamide—Anaemia—Prednisone—psoriasis	0.000149	0.0008	CcSEcCtD
Flutamide—Thrombocytopenia—Dexamethasone—psoriasis	0.000148	0.000795	CcSEcCtD
Flutamide—Thrombocytopenia—Betamethasone—psoriasis	0.000148	0.000795	CcSEcCtD
Flutamide—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000148	0.00275	CbGpPWpGaD
Flutamide—Nausea—Mycophenolic acid—psoriasis	0.000146	0.000785	CcSEcCtD
Flutamide—Feeling abnormal—Hydrocortisone—psoriasis	0.000146	0.000783	CcSEcCtD
Flutamide—Malaise—Prednisone—psoriasis	0.000146	0.000781	CcSEcCtD
Flutamide—Anorexia—Betamethasone—psoriasis	0.000144	0.000774	CcSEcCtD
Flutamide—Anorexia—Dexamethasone—psoriasis	0.000144	0.000774	CcSEcCtD
Flutamide—Fatigue—Triamcinolone—psoriasis	0.000144	0.000771	CcSEcCtD
Flutamide—Asthenia—Cyclosporine—psoriasis	0.000143	0.000767	CcSEcCtD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000141	0.00262	CbGpPWpGaD
Flutamide—Pruritus—Cyclosporine—psoriasis	0.000141	0.000756	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.00014	0.00261	CbGpPWpGaD
Flutamide—Asthenia—Mycophenolate mofetil—psoriasis	0.00014	0.000748	CcSEcCtD
Flutamide—Hypertension—Prednisone—psoriasis	0.000139	0.000748	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.000139	0.00258	CbGpPWpGaD
Flutamide—Pruritus—Mycophenolate mofetil—psoriasis	0.000138	0.000738	CcSEcCtD
Flutamide—Feeling abnormal—Triamcinolone—psoriasis	0.000137	0.000737	CcSEcCtD
Flutamide—Anxiety—Prednisone—psoriasis	0.000137	0.000735	CcSEcCtD
Flutamide—Insomnia—Dexamethasone—psoriasis	0.000137	0.000734	CcSEcCtD
Flutamide—Insomnia—Betamethasone—psoriasis	0.000137	0.000734	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000137	0.000732	CcSEcCtD
Flutamide—Diarrhoea—Cyclosporine—psoriasis	0.000136	0.000731	CcSEcCtD
Flutamide—Discomfort—Prednisone—psoriasis	0.000136	0.000728	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000135	0.00252	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000135	0.00252	CbGpPWpGaD
Flutamide—Erythema—Methotrexate—psoriasis	0.000135	0.000724	CcSEcCtD
Flutamide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000133	0.000713	CcSEcCtD
Flutamide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000132	0.00246	CbGpPWpGaD
Flutamide—Dizziness—Cyclosporine—psoriasis	0.000132	0.000707	CcSEcCtD
Flutamide—Oedema—Prednisone—psoriasis	0.000132	0.000707	CcSEcCtD
Flutamide—Decreased appetite—Dexamethasone—psoriasis	0.000132	0.000705	CcSEcCtD
Flutamide—Decreased appetite—Betamethasone—psoriasis	0.000132	0.000705	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—TP53—psoriasis	0.000131	0.00243	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000131	0.00243	CbGpPWpGaD
Flutamide—Fatigue—Dexamethasone—psoriasis	0.00013	0.0007	CcSEcCtD
Flutamide—Fatigue—Betamethasone—psoriasis	0.00013	0.0007	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000129	0.00239	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—JUN—psoriasis	0.000129	0.00239	CbGpPWpGaD
Flutamide—Dizziness—Mycophenolate mofetil—psoriasis	0.000129	0.000689	CcSEcCtD
Flutamide—Skin disorder—Prednisone—psoriasis	0.000128	0.000686	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000128	0.00237	CbGpPWpGaD
Flutamide—Asthenia—Hydrocortisone—psoriasis	0.000127	0.000682	CcSEcCtD
Flutamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000127	0.00236	CbGpPWpGaD
Flutamide—Vomiting—Cyclosporine—psoriasis	0.000127	0.00068	CcSEcCtD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000127	0.00235	CbGpPWpGaD
Flutamide—Rash—Cyclosporine—psoriasis	0.000126	0.000674	CcSEcCtD
Flutamide—Anorexia—Prednisone—psoriasis	0.000126	0.000674	CcSEcCtD
Flutamide—Dermatitis—Cyclosporine—psoriasis	0.000126	0.000673	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000125	0.00233	CbGpPWpGaD
Flutamide—Pruritus—Hydrocortisone—psoriasis	0.000125	0.000672	CcSEcCtD
Flutamide—Ill-defined disorder—Methotrexate—psoriasis	0.000125	0.000671	CcSEcCtD
Flutamide—Headache—Cyclosporine—psoriasis	0.000125	0.00067	CcSEcCtD
Flutamide—Anaemia—Methotrexate—psoriasis	0.000125	0.000669	CcSEcCtD
Flutamide—Feeling abnormal—Dexamethasone—psoriasis	0.000125	0.000669	CcSEcCtD
Flutamide—Feeling abnormal—Betamethasone—psoriasis	0.000125	0.000669	CcSEcCtD
Flutamide—Vomiting—Mycophenolate mofetil—psoriasis	0.000124	0.000663	CcSEcCtD
Flutamide—Rash—Mycophenolate mofetil—psoriasis	0.000123	0.000657	CcSEcCtD
Flutamide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000122	0.000657	CcSEcCtD
Flutamide—Headache—Mycophenolate mofetil—psoriasis	0.000122	0.000653	CcSEcCtD
Flutamide—Malaise—Methotrexate—psoriasis	0.000122	0.000653	CcSEcCtD
Flutamide—Diarrhoea—Hydrocortisone—psoriasis	0.000121	0.00065	CcSEcCtD
Flutamide—Leukopenia—Methotrexate—psoriasis	0.000121	0.000648	CcSEcCtD
Flutamide—Dizziness—Prednisolone—psoriasis	0.00012	0.000643	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—IL6—psoriasis	0.00012	0.00223	CbGpPWpGaD
Flutamide—Asthenia—Triamcinolone—psoriasis	0.00012	0.000642	CcSEcCtD
Flutamide—Insomnia—Prednisone—psoriasis	0.000119	0.000639	CcSEcCtD
Flutamide—Nausea—Cyclosporine—psoriasis	0.000118	0.000635	CcSEcCtD
Flutamide—Pruritus—Triamcinolone—psoriasis	0.000118	0.000633	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—CARM1—psoriasis	0.000118	0.00218	CbGpPWpGaD
Flutamide—Dizziness—Hydrocortisone—psoriasis	0.000117	0.000628	CcSEcCtD
Flutamide—Nausea—Mycophenolate mofetil—psoriasis	0.000116	0.000619	CcSEcCtD
Flutamide—Decreased appetite—Prednisone—psoriasis	0.000115	0.000614	CcSEcCtD
Flutamide—Rash—Prednisolone—psoriasis	0.000114	0.000613	CcSEcCtD
Flutamide—Dermatitis—Prednisolone—psoriasis	0.000114	0.000613	CcSEcCtD
Flutamide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000114	0.00212	CbGpPWpGaD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000114	0.000612	CcSEcCtD
Flutamide—Fatigue—Prednisone—psoriasis	0.000114	0.000609	CcSEcCtD
Flutamide—Headache—Prednisolone—psoriasis	0.000114	0.000609	CcSEcCtD
Flutamide—Discomfort—Methotrexate—psoriasis	0.000114	0.000609	CcSEcCtD
Flutamide—Constipation—Prednisone—psoriasis	0.000113	0.000604	CcSEcCtD
Flutamide—Vomiting—Hydrocortisone—psoriasis	0.000113	0.000604	CcSEcCtD
Flutamide—Rash—Hydrocortisone—psoriasis	0.000112	0.000599	CcSEcCtD
Flutamide—Dermatitis—Hydrocortisone—psoriasis	0.000112	0.000598	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000111	0.00207	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—STAT3—psoriasis	0.000111	0.00207	CbGpPWpGaD
Flutamide—Confusional state—Methotrexate—psoriasis	0.000111	0.000596	CcSEcCtD
Flutamide—Headache—Hydrocortisone—psoriasis	0.000111	0.000595	CcSEcCtD
Flutamide—Dizziness—Triamcinolone—psoriasis	0.00011	0.000591	CcSEcCtD
Flutamide—Feeling abnormal—Prednisone—psoriasis	0.000109	0.000582	CcSEcCtD
Flutamide—Asthenia—Betamethasone—psoriasis	0.000109	0.000582	CcSEcCtD
Flutamide—Asthenia—Dexamethasone—psoriasis	0.000109	0.000582	CcSEcCtD
Flutamide—Thrombocytopenia—Methotrexate—psoriasis	0.000108	0.000578	CcSEcCtD
Flutamide—Nausea—Prednisolone—psoriasis	0.000108	0.000578	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000107	0.00199	CbGpPWpGaD
Flutamide—Pruritus—Dexamethasone—psoriasis	0.000107	0.000574	CcSEcCtD
Flutamide—Pruritus—Betamethasone—psoriasis	0.000107	0.000574	CcSEcCtD
Flutamide—Skin disorder—Methotrexate—psoriasis	0.000107	0.000574	CcSEcCtD
Flutamide—Vomiting—Triamcinolone—psoriasis	0.000106	0.000569	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000105	0.00196	CbGpPWpGaD
Flutamide—Nausea—Hydrocortisone—psoriasis	0.000105	0.000564	CcSEcCtD
Flutamide—Rash—Triamcinolone—psoriasis	0.000105	0.000564	CcSEcCtD
Flutamide—Dermatitis—Triamcinolone—psoriasis	0.000105	0.000563	CcSEcCtD
Flutamide—Anorexia—Methotrexate—psoriasis	0.000105	0.000563	CcSEcCtD
Flutamide—Headache—Triamcinolone—psoriasis	0.000104	0.00056	CcSEcCtD
Flutamide—Diarrhoea—Betamethasone—psoriasis	0.000104	0.000555	CcSEcCtD
Flutamide—Diarrhoea—Dexamethasone—psoriasis	0.000104	0.000555	CcSEcCtD
Flutamide—Dizziness—Dexamethasone—psoriasis	0.0001	0.000537	CcSEcCtD
Flutamide—Dizziness—Betamethasone—psoriasis	0.0001	0.000537	CcSEcCtD
Flutamide—Insomnia—Methotrexate—psoriasis	9.96e-05	0.000534	CcSEcCtD
Flutamide—Nausea—Triamcinolone—psoriasis	9.91e-05	0.000531	CcSEcCtD
Flutamide—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	9.89e-05	0.00184	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.84e-05	0.00183	CbGpPWpGaD
Flutamide—Somnolence—Methotrexate—psoriasis	9.79e-05	0.000525	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	9.73e-05	0.00181	CbGpPWpGaD
Flutamide—Vomiting—Betamethasone—psoriasis	9.62e-05	0.000516	CcSEcCtD
Flutamide—Vomiting—Dexamethasone—psoriasis	9.62e-05	0.000516	CcSEcCtD
Flutamide—Decreased appetite—Methotrexate—psoriasis	9.58e-05	0.000513	CcSEcCtD
Flutamide—Rash—Betamethasone—psoriasis	9.54e-05	0.000512	CcSEcCtD
Flutamide—Rash—Dexamethasone—psoriasis	9.54e-05	0.000512	CcSEcCtD
Flutamide—Dermatitis—Betamethasone—psoriasis	9.53e-05	0.000511	CcSEcCtD
Flutamide—Dermatitis—Dexamethasone—psoriasis	9.53e-05	0.000511	CcSEcCtD
Flutamide—Fatigue—Methotrexate—psoriasis	9.5e-05	0.000509	CcSEcCtD
Flutamide—Headache—Betamethasone—psoriasis	9.48e-05	0.000508	CcSEcCtD
Flutamide—Headache—Dexamethasone—psoriasis	9.48e-05	0.000508	CcSEcCtD
Flutamide—Asthenia—Prednisone—psoriasis	9.46e-05	0.000507	CcSEcCtD
Flutamide—Pruritus—Prednisone—psoriasis	9.33e-05	0.0005	CcSEcCtD
Flutamide—Feeling abnormal—Methotrexate—psoriasis	9.08e-05	0.000487	CcSEcCtD
Flutamide—Diarrhoea—Prednisone—psoriasis	9.02e-05	0.000484	CcSEcCtD
Flutamide—Nausea—Dexamethasone—psoriasis	8.99e-05	0.000482	CcSEcCtD
Flutamide—Nausea—Betamethasone—psoriasis	8.99e-05	0.000482	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.84e-05	0.00164	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—NDUFA5—psoriasis	8.78e-05	0.00163	CbGpPWpGaD
Flutamide—Dizziness—Prednisone—psoriasis	8.72e-05	0.000467	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	8.43e-05	0.00157	CbGpPWpGaD
Flutamide—Vomiting—Prednisone—psoriasis	8.38e-05	0.000449	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	8.34e-05	0.00155	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.34e-05	0.00155	CbGpPWpGaD
Flutamide—Rash—Prednisone—psoriasis	8.31e-05	0.000446	CcSEcCtD
Flutamide—Dermatitis—Prednisone—psoriasis	8.3e-05	0.000445	CcSEcCtD
Flutamide—Headache—Prednisone—psoriasis	8.26e-05	0.000443	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—JUN—psoriasis	8.22e-05	0.00153	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.22e-05	0.00153	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.19e-05	0.00152	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	8.12e-05	0.00151	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.91e-05	0.00147	CbGpPWpGaD
Flutamide—Asthenia—Methotrexate—psoriasis	7.9e-05	0.000424	CcSEcCtD
Flutamide—Nausea—Prednisone—psoriasis	7.83e-05	0.00042	CcSEcCtD
Flutamide—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	7.82e-05	0.00145	CbGpPWpGaD
Flutamide—Pruritus—Methotrexate—psoriasis	7.79e-05	0.000418	CcSEcCtD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	7.65e-05	0.00142	CbGpPWpGaD
Flutamide—Diarrhoea—Methotrexate—psoriasis	7.54e-05	0.000404	CcSEcCtD
Flutamide—CYP1B1—Metabolism—CYP2S1—psoriasis	7.47e-05	0.00139	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	7.37e-05	0.00137	CbGpPWpGaD
Flutamide—Dizziness—Methotrexate—psoriasis	7.28e-05	0.000391	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.18e-05	0.00133	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.1e-05	0.00132	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—VDR—psoriasis	7.02e-05	0.0013	CbGpPWpGaD
Flutamide—Vomiting—Methotrexate—psoriasis	7e-05	0.000376	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.99e-05	0.0013	CbGpPWpGaD
Flutamide—Rash—Methotrexate—psoriasis	6.95e-05	0.000372	CcSEcCtD
Flutamide—Dermatitis—Methotrexate—psoriasis	6.94e-05	0.000372	CcSEcCtD
Flutamide—Headache—Methotrexate—psoriasis	6.9e-05	0.00037	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.84e-05	0.00127	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.73e-05	0.00125	CbGpPWpGaD
Flutamide—Nausea—Methotrexate—psoriasis	6.54e-05	0.000351	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.2e-05	0.00115	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—TNF—psoriasis	6.15e-05	0.00114	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.11e-05	0.00113	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—NDUFA5—psoriasis	5.73e-05	0.00106	CbGpPWpGaD
Flutamide—AR—Gene Expression—CARM1—psoriasis	5.66e-05	0.00105	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	5.57e-05	0.00103	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—NDUFA5—psoriasis	5.41e-05	0.00101	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.32e-05	0.000988	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.32e-05	0.000988	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	5.27e-05	0.00098	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.23e-05	0.000972	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.04e-05	0.000937	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—IL6—psoriasis	4.97e-05	0.000923	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—PPARG—psoriasis	4.89e-05	0.000909	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYP2S1—psoriasis	4.87e-05	0.000905	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.61e-05	0.000857	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYP2S1—psoriasis	4.6e-05	0.000855	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—NDUFA5—psoriasis	4.43e-05	0.000823	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.13e-05	0.000767	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.91e-05	0.000727	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYP2S1—psoriasis	3.76e-05	0.000699	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CARM1—psoriasis	3.65e-05	0.000678	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—NDUFA5—psoriasis	3.45e-05	0.000641	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.41e-05	0.000634	CbGpPWpGaD
Flutamide—AR—Gene Expression—VDR—psoriasis	3.38e-05	0.000628	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.22e-05	0.000598	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYP2S1—psoriasis	2.93e-05	0.000545	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—NDUFA5—psoriasis	2.66e-05	0.000495	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.41e-05	0.000448	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CARM1—psoriasis	2.38e-05	0.000442	CbGpPWpGaD
Flutamide—AR—Gene Expression—PPARG—psoriasis	2.36e-05	0.000438	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CYP2S1—psoriasis	2.26e-05	0.000421	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CARM1—psoriasis	2.25e-05	0.000417	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CAT—psoriasis	2.24e-05	0.000417	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.1e-05	0.00039	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.97e-05	0.000367	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CARM1—psoriasis	1.84e-05	0.000342	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—APOE—psoriasis	1.74e-05	0.000324	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.72e-05	0.000319	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.54e-05	0.000286	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PPARG—psoriasis	1.52e-05	0.000282	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CAT—psoriasis	1.46e-05	0.000272	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CARM1—psoriasis	1.43e-05	0.000266	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CAT—psoriasis	1.38e-05	0.000257	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.34e-05	0.000249	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—APOE—psoriasis	1.14e-05	0.000211	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CAT—psoriasis	1.13e-05	0.00021	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CARM1—psoriasis	1.11e-05	0.000205	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—APOE—psoriasis	1.07e-05	0.000199	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PPARG—psoriasis	9.9e-06	0.000184	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PPARG—psoriasis	9.35e-06	0.000174	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CAT—psoriasis	8.81e-06	0.000164	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—APOE—psoriasis	8.78e-06	0.000163	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PPARG—psoriasis	7.65e-06	0.000142	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—APOE—psoriasis	6.85e-06	0.000127	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CAT—psoriasis	6.8e-06	0.000126	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PPARG—psoriasis	5.96e-06	0.000111	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—APOE—psoriasis	5.28e-06	9.82e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PPARG—psoriasis	4.6e-06	8.55e-05	CbGpPWpGaD
